kyowa Kirin
Mr. Masashi Miyamoto Ph.D. (Pres, CEO & Representative Director)
Mr. Motohiko Kawaguchi (CFO & Head of Global Fin.)
Mr. Yutaka Osawa M.B.A. (CCO & Representative Director)
Summary
History
On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.
On July 11, 2014, the KHK subsidiary, ProStrakan Group , acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million In 2019, the entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd.
In November 2022, Kyowa Kirin announced plans to spin its international established medicines portfolio into a new joint venture with German company Grünenthal.
Key Team
Satoko Yoshida (Head of Global Corp. Communications)
Hiroshi Sonekawa (Head of Japan Sales & Marketing)
Wataru Murata M.B.A. (Head of Global HR)
Dr. Toshifumi Mikayama Ph.D. (Chief International Bus. Officer & Director)
Takeyoshi Yamashita Ph.D. (Chief Strategy Officer)
Yasuo Fujii M.B.A. (Head of Global Bus. Devel.)
Jean-David Rafizadeh-Kabe J.D., M.D. (Head of Global Pharmacovigilance)
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Mr. Masashi Miyamoto Ph.D. (Pres, CEO & Representative Director)
Mr. Motohiko Kawaguchi (CFO & Head of Global Fin.)
Mr. Yutaka Osawa M.B.A. (CCO & Representative Director)